Skip to content

Iambic Therapeutics

Iambic Therapeutics is a biotech company that uses AI to design differentiated drug candidates, with a clinical pipeline targeting HER2, KIF18A, and CDK2/4.

50

Overview

Iambic Therapeutics is a biotechnology company that applies artificial intelligence to drug discovery, aiming to deliver differentiated drug candidates for unmet patient needs. The company's molecular superintelligence platform combines AI technologies with high-throughput experimentation to convert novel molecular designs into biological insights on a weekly basis.

The Molecular Superintelligence Platform

At the core of Iambic's approach is a platform that integrates AI with automated experimentation. The company states that its platform delivers differentiated drug candidates optimized for patient and partner impact. By pairing computational design with physical testing, Iambic seeks to shorten the cycle from molecular idea to biological data.

Enchant and NeuralPLexer AI Technologies

Iambic's AI stack includes Enchant and NeuralPLexer, which are described as multimodal transformer and co-folding technologies built specifically for drug discovery. These tools are designed to handle the complexity of molecular interactions and to guide the design of new compounds. The company positions these technologies as central to its ability to tackle challenging targets.

High-Throughput Experimentation and Automation

The platform drives a high-throughput experimental engine that generates new biological data each week. This automation allows Iambic to test many molecular designs in parallel, feeding results back into the AI models. The company says this cycle enables rapid iteration and helps identify promising candidates more efficiently than traditional methods.

A Pipeline of Differentiated Drug Candidates

Iambic's proprietary pipeline includes several clinical and preclinical programs. IAM1363 is a selective, brain-penetrant inhibitor for HER2-driven cancers that has shown anti-tumor activity and tolerability in Phase 1/1b studies. IAM217 is a differentiated, brain-penetrant inhibitor for ovarian cancer, triple-negative breast cancer, and other solid tumors; it has an IND submitted. IAM-C1 is a selective CDK2/4 small-molecule inhibitor for HR+/HER2- breast cancer and CCNE1 amplified cancers, currently in IND-enabling studies. The company states that its pipeline has been delivered at a pace years faster than the industry standard.

Targeting Known and Undruggable Targets

Iambic aims to unlock the untapped potential of known targets and to transform seemingly undruggable targets into opportunities for breakthrough treatments. By applying its AI platform to these challenging areas, the company hopes to expand the range of addressable disease targets.

Collaboration Between AI Experts and Drug Hunters

Iambic emphasizes that its innovations are placed in the hands of seasoned drug hunters. This collaboration between AI specialists and experienced discovery scientists is intended to optimize the path toward differentiated therapeutics. The company's leadership and team bring together expertise from both computational and experimental backgrounds.

Recent Developments

Iambic provides updates on its pipeline and corporate milestones through its news section. The company's progress includes advancing IAM1363 into Phase 1/1b and submitting an IND for IAM217. These steps reflect the company's transition from platform development to clinical execution.

Core features

  • Molecular superintelligence platform that integrates AI with high-throughput experimentation
  • Enchant and NeuralPLexer AI technologies for multimodal transformer and co-folding drug discovery
  • AI-driven, high-throughput experimentation to generate new biological data weekly
  • Proprietary pipeline of differentiated clinical candidates
  • Focus on known and undruggable targets
  • Collaboration between AI experts and drug hunters

Use cases

  1. 1Discovering selective inhibitors for hard-to-treat cancers
  2. 2Optimizing drug candidates for patient and partner impact
  3. 3Accelerating preclinical development through AI-driven experimentation
  4. 4Advancing clinical programs in oncology

Strengths and things to check

Strengths

  • AI platform purpose-built for drug discovery
  • High-throughput experimentation yields weekly biological insights
  • Pipeline includes clinical-stage candidates
  • Team combines AI and drug-hunting expertise

Things to check

  • Clinical candidates are still in early phases
  • Platform details are proprietary and not fully disclosed
  • No public pricing or access information for external users

Pricing

Subscription pricing is not listed.

Basic information

Website
iambic.ai
Added
Oct 10, 2026
Platforms
Web
Chinese & English
Not marked
API
Marked as supported
Self-hosting
Not marked
Best for
Iambic Therapeutics serves drug discovery researchers, pharmaceutical partners, and investors seeking AI-driven therapeutic development.
Information updated
Oct 16, 2026
Website status
Checking
Corrections · Privacy · Data requests?
Contact us

Features, pricing and availability may change. Always verify details on the official website. Maintained by steven · Last updated Oct 16, 2026 →

Related tools

All categories

Nabla

Enterprise Grade

Nabla is a clinical AI layer that captures patient-clinician conversations and generates structured notes, dictation, and coding suggestions inside Epic and major EHRs.

Enterprise GradeAPI Available
60
Free TierSOC 2
View details

Wysa

Enterprise Grade

Wysa is an AI-powered mental health support platform that offers safe, clinically backed care for individuals, teams, and health systems. It provides self-help, guided referral, and between-session support through an always-available, anonymous chat interface.

Enterprise GradeAPI Available
60
Free Tier
View details